| Year |
Citation |
Score |
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Juvet T, Prassas I, Trachtenberg J, Toi A, Fraser M, et al. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute. 109. PMID 28376164 DOI: 10.1093/Jnci/Djw258 |
0.36 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, et al. PD65-01 GERMLINE MUTATIONS IN THE KALLIKREIN 6 REGION AND PREDISPOSITION FOR AGGRESSIVE PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2951 |
0.329 |
|
| 2015 |
Pabalan N, Jarjanazi H, Ozcelik H. Associations of the Insertion/Deletion Polymorphism in the ACE Gene and Risk of Gastric Cancer: A Meta-Analysis. Journal of Gastrointestinal Cancer. 46: 370-9. PMID 26307111 DOI: 10.1007/S12029-015-9754-8 |
0.675 |
|
| 2015 |
Özo?uz A, Uyan Ö, Birdal G, Iskender C, Kartal E, Lahut S, Ömür Ö, Agim ZS, Eken AG, Sen NE, Kavak P, Sayg? C, Sapp PC, Keagle P, Parman Y, et al. The distinct genetic pattern of ALS in Turkey and novel mutations. Neurobiology of Aging. 36: 1764.e9-18. PMID 25681989 DOI: 10.1016/J.Neurobiolaging.2014.12.032 |
0.685 |
|
| 2014 |
Kang S, Savas S, Ozcelik H, Briollais L. Inferring gene network from candidate SNP association studies using a Bayesian graphical model: application to a breast cancer case-control study from ontario. Human Heredity. 78: 140-52. PMID 25342289 DOI: 10.1159/000365923 |
0.414 |
|
| 2014 |
Cotterchio M, Mirea L, Ozcelik H, Kreiger N. Active cigarette smoking, variants in carcinogen metabolism genes and breast cancer risk among pre- and postmenopausal women in Ontario, Canada. The Breast Journal. 20: 468-80. PMID 25052559 DOI: 10.1111/Tbj.12304 |
0.376 |
|
| 2014 |
Pabalan N, Jarjanazi H, Ozcelik H. The impact of capsaicin intake on risk of developing gastric cancers: a meta-analysis. Journal of Gastrointestinal Cancer. 45: 334-41. PMID 24756832 DOI: 10.1007/S12029-014-9610-2 |
0.642 |
|
| 2014 |
Briollais L, Xu J, Kwiatkowski M, Friedlander M, Recker F, Kuk C, Hanna S, Fleshner NE, Bapat B, Juvet T, Li H, van der Kwast TH, Diamandis EP, Zlotta AR, Ozcelik H. MP49-20 FINE-MAPPING OF THE KALLIKREIN REGION AND ITS ROLE IN PROSTATE CANCER AGGRESSIVENESS: RESULTS FROM A CANADIAN COHORT AND THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1121 |
0.312 |
|
| 2013 |
John EM, McGuire V, Thomas D, Haile R, Ozcelik H, Milne RL, Felberg A, West DW, Miron A, Knight JA, Terry MB, Daly M, Buys SS, Andrulis IL, Hopper JL, et al. Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1547-56. PMID 23853209 DOI: 10.1158/1055-9965.Epi-13-0189 |
0.436 |
|
| 2013 |
Tram E, Savas S, Ozcelik H. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2. Plos One. 8: e62468. PMID 23704879 DOI: 10.1371/Journal.Pone.0062468 |
0.417 |
|
| 2013 |
Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. Plos Genetics. 9: e1003212. PMID 23544013 DOI: 10.1371/Journal.Pgen.1003212 |
0.46 |
|
| 2013 |
Pabalan N, Jarjanazi H, Ozcelik H. A meta-analysis of the C1420T polymorphism in cytosolic serine hydroxymethyltransferase (SHMT1) among Caucasian colorectal cancer populations. International Journal of Colorectal Disease. 28: 925-32. PMID 23322534 DOI: 10.1007/S00384-013-1639-3 |
0.67 |
|
| 2013 |
Agim ZS, Esendal M, Briollais L, Uyan O, Meschian M, Martinez LA, Ding Y, Basak AN, Ozcelik H. Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia. Plos One. 8: e53042. PMID 23301017 DOI: 10.1371/Journal.Pone.0053042 |
0.755 |
|
| 2013 |
Pabalan N, Jarjanazi H, Ozcelik H. Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment. 137: 553-8. PMID 23225146 DOI: 10.1007/S10549-012-2364-2 |
0.703 |
|
| 2013 |
Olkhov-Mitsel E, Kwast TVd, Kron K, Ozcelik H, Briollais L, Fleshner N, Diamandis E, Zlotta A, Bapat B. Abstract B21: Epigenetic and post-transcriptional regulation of the kallikrein gene family as a novel panel of prostate cancer biomarkers Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-B21 |
0.324 |
|
| 2012 |
Pabalan N, Francisco-Pabalan O, Jarjanazi H, Li H, Sung L, Ozcelik H. Racial and tissue-specific cancer risk associated with PARP1 (ADPRT) Val762Ala polymorphism: a meta-analysis. Molecular Biology Reports. 39: 11061-72. PMID 23073772 DOI: 10.1007/S11033-012-2009-X |
0.685 |
|
| 2012 |
Ozcelik H, Shi X, Chang MC, Tram E, Vlasschaert M, Di Nicola N, Kiselova A, Yee D, Goldman A, Dowar M, Sukhu B, Kandel R, Siminovitch K. Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. The Journal of Molecular Diagnostics : Jmd. 14: 467-75. PMID 22874498 DOI: 10.1016/J.Jmoldx.2012.03.006 |
0.47 |
|
| 2012 |
Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1362-70. PMID 22729394 DOI: 10.1158/1055-9965.Epi-12-0229 |
0.493 |
|
| 2012 |
Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, et al. Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer. 106: 2016-24. PMID 22669161 DOI: 10.1038/Bjc.2012.160 |
0.483 |
|
| 2012 |
Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, et al. The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics. 21: 3926-39. PMID 22532573 DOI: 10.1093/Hmg/Dds159 |
0.41 |
|
| 2012 |
Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. Plos One. 7: e32389. PMID 22427832 DOI: 10.1371/Journal.Pone.0032389 |
0.717 |
|
| 2012 |
Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 645-57. PMID 22351618 DOI: 10.1158/1055-9965.Epi-11-0888 |
0.496 |
|
| 2012 |
Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research : Bcr. 14: R33. PMID 22348646 DOI: 10.1186/Bcr3121 |
0.467 |
|
| 2012 |
Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation. 33: 690-702. PMID 22253144 DOI: 10.1002/Humu.22025 |
0.481 |
|
| 2012 |
Anderson LN, Cotterchio M, Mirea L, Ozcelik H, Kreiger N. Passive cigarette smoke exposure during various periods of life, genetic variants, and breast cancer risk among never smokers. American Journal of Epidemiology. 175: 289-301. PMID 22247046 DOI: 10.1093/Aje/Kwr324 |
0.365 |
|
| 2011 |
Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 13: R110. PMID 22053997 DOI: 10.1186/Bcr3052 |
0.476 |
|
| 2011 |
Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, Miron A, Andrulis IL, Hopper JL, Knight JA, Ozcelik H, Dite GS, Apicella C, Southey MC, Whittemore AS. Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4505-9. PMID 22042950 DOI: 10.1200/Jco.2010.34.4440 |
0.445 |
|
| 2011 |
Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL, et al. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics. 20: 4732-47. PMID 21890493 DOI: 10.1093/Hmg/Ddr388 |
0.514 |
|
| 2011 |
Tram E, Ibrahim-Zada I, Briollais L, Knight JA, Andrulis IL, Ozcelik H. Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR). Breast Cancer Research : Bcr. 13: R77. PMID 21835029 DOI: 10.1186/Bcr2926 |
0.396 |
|
| 2011 |
Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics. 130: 685-99. PMID 21597964 DOI: 10.1007/S00439-011-1003-Z |
0.331 |
|
| 2011 |
Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics. 20: 3304-21. PMID 21593217 DOI: 10.1093/Hmg/Ddr226 |
0.509 |
|
| 2011 |
Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozcelik H, Tuzmen S. NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. Plos One. 6: e18306. PMID 21483694 DOI: 10.1371/Journal.Pone.0018306 |
0.767 |
|
| 2011 |
Eng L, Ibrahim-zada I, Jarjanazi H, Savas S, Meschian M, Pritchard KI, Ozcelik H. Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. Bmc Medical Genomics. 4: 18. PMID 21314952 DOI: 10.1186/1755-8794-4-18 |
0.707 |
|
| 2011 |
Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, Daly MB, Godwin AK, Buys SS, et al. Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Research : Bcr. 13: R14. PMID 21281505 DOI: 10.1186/Bcr2822 |
0.433 |
|
| 2011 |
Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 103: 105-16. PMID 21169536 DOI: 10.1093/Jnci/Djq494 |
0.544 |
|
| 2010 |
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Research. 70: 9742-54. PMID 21118973 DOI: 10.1158/0008-5472.Can-10-1907 |
0.496 |
|
| 2010 |
Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. Plos Genetics. 6: e1001183. PMID 21060860 DOI: 10.1371/Journal.Pgen.1001183 |
0.517 |
|
| 2010 |
Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nature Genetics. 42: 885-92. PMID 20852631 DOI: 10.1038/Ng.669 |
0.486 |
|
| 2010 |
Savas S, Briollais L, Ibrahim-zada I, Jarjanazi H, Choi YH, Musquera M, Fleshner N, Venkateswaran V, Ozcelik H. A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance. Plos One. 5: e12601. PMID 20830292 DOI: 10.1371/Journal.Pone.0012601 |
0.698 |
|
| 2010 |
Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Research and Treatment. 124: 531-41. PMID 20379847 DOI: 10.1007/S10549-010-0863-6 |
0.706 |
|
| 2010 |
Fehringer G, Ozcelik H, Knight JA, Paterson AD, Dite GS, Giles GG, Southey MC, Andrulis IL, Hopper JL, Boyd NF. Family-based association study of IGF1 microsatellites and height, weight, and body mass index. Journal of Human Genetics. 55: 255-8. PMID 20300125 DOI: 10.1038/Jhg.2010.17 |
0.308 |
|
| 2010 |
Kron KJ, Liu L, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B. DNA methylation of HOXD3 as a marker of prostate cancer progression. Laboratory Investigation; a Journal of Technical Methods and Pathology. 90: 1060-7. PMID 20212450 DOI: 10.1038/Labinvest.2010.57 |
0.328 |
|
| 2010 |
Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, et al. Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer Plos Genetics. 6. DOI: 10.1371/Annotation/B28Cf02D-7196-4A16-8B36-6562A0B84F75 |
0.404 |
|
| 2010 |
Ibrahim-zada I, Eng L, Parissenti A, Pritchard KI, Ozcelik H. Abstract 3586: Reactive oxygen species and antioxidant pathway in resistance to doxorubicin and paclitaxel in cancer Cancer Research. 70: 3586-3586. DOI: 10.1158/1538-7445.Am10-3586 |
0.437 |
|
| 2010 |
Eng L, Ibrahim-zada I, Jarjanazi H, Savas S, Pritchard KI, Ozcelik H. Abstract 1679: Identification of pharmacogenomic markers associated with paclitaxel and carboplatin response in cancer: The cross-talk between agents Cancer Research. 70: 1679-1679. DOI: 10.1158/1538-7445.Am10-1679 |
0.721 |
|
| 2009 |
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S, Neuhausen SL, Ding YC, Couch FJ, et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer. 101: 2048-54. PMID 19920816 DOI: 10.1038/Sj.Bjc.6605416 |
0.507 |
|
| 2009 |
Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X, Neuhausen SL, Ding YC, Couch FJ, Wang X, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics. 18: 4442-56. PMID 19656774 DOI: 10.1093/Hmg/Ddp372 |
0.513 |
|
| 2009 |
Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. Plos One. 4: e4830. PMID 19283074 DOI: 10.1371/Journal.Pone.0004830 |
0.391 |
|
| 2009 |
Fehringer G, Boyd NF, Knight JA, Paterson AD, Dite GS, Giles GG, Southey MC, Andrulis IL, Hopper JL, Ozcelik H. Family-based genetic association study of insulin-like growth factor I microsatellite markers and premenopausal breast cancer risk. Breast Cancer Research and Treatment. 118: 415-24. PMID 19229608 DOI: 10.1007/S10549-009-0336-Y |
0.421 |
|
| 2009 |
Fehringer G, Ozcelik H, Knight JA, Paterson AD, Boyd NF. Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women. Breast Cancer Research and Treatment. 116: 413-23. PMID 18785005 DOI: 10.1007/S10549-008-0146-7 |
0.313 |
|
| 2009 |
Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Research and Treatment. 116: 379-86. PMID 18704680 DOI: 10.1007/S10549-008-0153-8 |
0.426 |
|
| 2008 |
Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 2773-81. PMID 18843022 DOI: 10.1158/1055-9965.Epi-08-0169 |
0.725 |
|
| 2008 |
Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. American Journal of Human Genetics. 82: 937-48. PMID 18355772 DOI: 10.1016/J.Ajhg.2008.02.008 |
0.516 |
|
| 2008 |
Jarjanazi H, Kiefer J, Savas S, Briollais L, Tuzmen S, Pabalan N, Ibrahim-Zada I, Mousses S, Ozcelik H. Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. Human Mutation. 29: 461-7. PMID 18330920 DOI: 10.1002/Humu.20732 |
0.774 |
|
| 2008 |
Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis IL, Blomqvist C, Nevanlinna H, Ozcelik H. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. Bmc Cancer. 8: 6. PMID 18194538 DOI: 10.1186/1471-2407-8-6 |
0.391 |
|
| 2008 |
Jarjanazi H, Savas S, Pabalan N, Dennis JW, Ozcelik H. Biological implications of SNPs in signal peptide domains of human proteins. Proteins. 70: 394-403. PMID 17680692 DOI: 10.1002/Prot.21548 |
0.639 |
|
| 2007 |
Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. American Journal of Human Genetics. 81: 1186-200. PMID 17999359 DOI: 10.1086/522611 |
0.463 |
|
| 2007 |
Briollais L, Wang Y, Rajendram I, Onay V, Shi E, Knight J, Ozcelik H. Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario. Bmc Medicine. 5: 22. PMID 17683639 DOI: 10.1186/1741-7015-5-22 |
0.461 |
|
| 2007 |
Apicella C, Dowty JG, Dite GS, Jenkins MA, Senie RT, Daly MB, Andrulis IL, John EM, Buys SS, Li FP, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, et al. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clinical Genetics. 72: 87-97. PMID 17661812 DOI: 10.1111/J.1399-0004.2007.00841.X |
0.403 |
|
| 2007 |
Figueiredo JC, Knight JA, Cho S, Savas S, Onay UV, Briollais L, Goodwin PJ, McLaughlin JR, Andrulis IL, Ozcelik H. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. Bmc Cancer. 7: 99. PMID 17567920 DOI: 10.1186/1471-2407-7-99 |
0.479 |
|
| 2007 |
Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. Breast Cancer Research and Treatment. 105: 255-65. PMID 17221157 DOI: 10.1007/s10549-006-9452-0 |
0.331 |
|
| 2006 |
Jarjanazi H, Li H, Andrulis IL, Ozcelik H. Genome wide screening of CAG trinucleotide repeat lengths in breast cancer. Disease Markers. 22: 343-9. PMID 17264405 DOI: 10.1155/2006/951857 |
0.705 |
|
| 2006 |
Yazici H, Tigli H, Kadehci Z, Kucucuk S, Saip P, Issever H, Ozcelik H, Dalay N. Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family? Oncology Research. 16: 43-7. PMID 16783967 DOI: 10.3727/000000006783981279 |
0.518 |
|
| 2006 |
Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H. SNP-SNP interactions in breast cancer susceptibility. Bmc Cancer. 6: 114. PMID 16672066 DOI: 10.1186/1471-2407-6-114 |
0.494 |
|
| 2006 |
Savas S, Schmidt S, Jarjanazi H, Ozcelik H. Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations. Human Genomics. 2: 287-96. PMID 16595073 DOI: 10.1186/1479-7364-2-5-287 |
0.713 |
|
| 2006 |
Savas S, Tuzmen S, Ozcelik H. Human SNPs resulting in premature stop codons and protein truncation. Human Genomics. 2: 274-86. PMID 16595072 DOI: 10.1186/1479-7364-2-5-274 |
0.757 |
|
| 2006 |
Cho S, Savas S, Ozcelik H. Genetic variation and the mitogen-activated protein kinase (MAPK) signaling pathway. Omics : a Journal of Integrative Biology. 10: 66-81. PMID 16584319 DOI: 10.1089/Omi.2006.10.66 |
0.33 |
|
| 2005 |
Savas S, Ahmad MF, Shariff M, Kim DY, Ozcelik H. Candidate nsSNPs that can affect the functions and interactions of cell cycle proteins. Proteins. 58: 697-705. PMID 15617026 DOI: 10.1002/Prot.20367 |
0.347 |
|
| 2004 |
Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genetics. 36: 979-83. PMID 15300251 DOI: 10.1038/Ng1408 |
0.779 |
|
| 2004 |
Figueiredo JC, Knight JA, Briollais L, Andrulis IL, Ozcelik H. Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 13: 583-91. PMID 15066923 |
0.331 |
|
| 2004 |
Knight JA, Onay UV, Wells S, Li H, Shi EJ, Andrulis IL, Ozcelik H. Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 13: 146-9. PMID 14744747 DOI: 10.1158/1055-9965.Epi-03-0164 |
0.496 |
|
| 2004 |
Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 86-96. PMID 14701769 DOI: 10.1200/Jco.2004.09.128 |
0.431 |
|
| 2002 |
Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer. 95: 2068-75. PMID 12412159 DOI: 10.1002/Cncr.10949 |
0.395 |
|
| 2002 |
Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, et al. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Human Mutation. 20: 65-73. PMID 12112659 DOI: 10.1002/Humu.10097 |
0.378 |
|
| 2002 |
Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Human Mutation. 20: 28-34. PMID 12112655 DOI: 10.1002/Humu.10090 |
0.434 |
|
| 2002 |
Jarjanazi H, Ozcelik H. Modified rapid expansion detection method to analyze Cag/CTG repeat expansions. Biotechniques. 32: 1006, 1008, 1010. PMID 12019772 DOI: 10.2144/02325Bm06 |
0.603 |
|
| 2002 |
Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, Ngan HY, Choy KW, Pang CP, Poon CS, Poon AY, Ozcelik H. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Human Mutation. 19: 307-8. PMID 11857749 DOI: 10.1002/Humu.9015 |
0.439 |
|
| 2001 |
Mousses S, Gokgoz N, Wunder JS, Ozcelik H, Bull S, Bell RS, Andrulis IL. p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas. British Journal of Cancer. 84: 1635-9. PMID 11401317 DOI: 10.1054/Bjoc.2001.1844 |
0.333 |
|
| 2001 |
Jarjanazi H, Gokgoz N, Andrulis IL, Ozcelik H. Trinucleotide repeat expansions in familial/sporadic breast/ovarian cancer: searching for novel predisposition genes Nature Genetics. 27: 99-99. DOI: 10.1038/87386 |
0.699 |
|
| 2001 |
Onay UV, Knight AJ, Ozcelik H. Identifying the role of single-nucleotide polymorphisms in breast cancer risk using microarray and mass spectrometry technologies Nature Genetics. 27: 77-77. DOI: 10.1038/87234 |
0.428 |
|
| 2000 |
Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens Carcinogenesis. 21: 1761-1765. PMID 10964110 DOI: 10.1093/Carcin/21.9.1761 |
0.427 |
|
| 2000 |
Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients British Journal of Cancer. 83: 737-742. PMID 10952777 DOI: 10.1054/Bjoc.2000.1332 |
0.46 |
|
| 2000 |
Khoo US, Ngan HY, Cheung AN, Chan KY, Lu J, Chan VW, Lau S, Andrulis IL, Ozcelik H. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Human Mutation. 16: 88-9. PMID 10874312 DOI: 10.1002/1098-1004(200007)16:1<88::Aid-Humu16>3.0.Co;2-G |
0.459 |
|
| 2000 |
Kandel R, Li SQ, Ozcelik H, Rohan T. p53 protein accumulation and mutations in normal and benign breast tissue. International Journal of Cancer. 87: 73-78. PMID 10861455 DOI: 10.1002/1097-0215(20000701)87:1<73::Aid-Ijc11>3.0.Co;2-U |
0.427 |
|
| 1999 |
Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF, Poon CS, Leung YF, Loong F, Ip P, Chan GS, et al. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene. 18: 4643-6. PMID 10467410 DOI: 10.1038/Sj.Onc.1202847 |
0.479 |
|
| 1999 |
Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Prospero LD, Contiga V, Serruya C, Klein M, Moslehi R, et al. Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer Journal of the National Cancer Institute. 91: 1241-1247. PMID 10413426 DOI: 10.1093/Jnci/91.14.1241 |
0.449 |
|
| 1999 |
Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Andrulis IL. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. Journal of the National Cancer Institute. 91: 469-73. PMID 10070948 DOI: 10.1093/Jnci/91.5.469 |
0.403 |
|
| 1999 |
Chan PCR, Wong BYL, Ozcelik H, Cole DEC. Simple and Rapid Detection of BRCA1 and BRCA2 Mutations by Multiplex Mutagenically Separated PCR Clinical Chemistry. 45: 1285-1287. DOI: 10.1093/Clinchem/45.8.1285 |
0.491 |
|
| 1999 |
Ozcelik H, Knight JA. Microarray Technology to Study the Role of Genetic Polymorphisms in Breast Cancer Risk Nature Genetics. 23: 67-67. DOI: 10.1038/14380 |
0.484 |
|
| 1998 |
Ozçelik H, To MD, Couture J, Bull SB, Andrulis IL. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. International Journal of Cancer. Journal International Du Cancer. 77: 1-6. PMID 9639385 DOI: 10.1002/(Sici)1097-0215(19980703)77:1<1::Aid-Ijc1>3.0.Co;2-Y |
0.409 |
|
| 1997 |
Casson AG, Wilson SM, Mccart JA, O'Malley FP, Ozcelik H, Tsao MS, Chambers AF. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer International Journal of Cancer. 72: 739-745. PMID 9311587 DOI: 10.1002/(Sici)1097-0215(19970904)72:5<739::Aid-Ijc6>3.0.Co;2-T |
0.324 |
|
| 1997 |
Özcelik H, Schmocker B, Nicola ND, Shi X, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genetics. 16: 17-18. PMID 9140390 DOI: 10.1038/Ng0597-17 |
0.406 |
|
| 1996 |
Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86: 543-52. PMID 8752209 DOI: 10.1016/S0092-8674(00)80128-2 |
0.366 |
|
| Show low-probability matches. |